Based on this finding, two incretin-based medications were developed: (1) DPP-4 inhibitors that increase the concentration of GLP-1 by inhibiting it [22], and (2) GLP-1RAs, which act directly on the GLP-1 receptor [23]
The big elephant in the room is the medications are too expensive. The GLP-1 market has ballooned in recent years, as drugmakers race to find new variants and thereby seize a piece of a lucrative industry
For example, the natural compound salvianolic acid B (SalB), binds directly to the substrate pocket of DHHC5
The inability to sustain weight loss may be due to PYY 3-36 -induced Y2-R down-regulation and tolerance (i.e., tachyphylaxis) and/or activation of compensatory mechanisms in response to reduced food intake
Presented for research literature review only Chen X et al
These unapproved products pose additional risks for people attempting to microdose